Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
02
11
2023
accepted:
15
01
2024
revised:
11
01
2024
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
29
1
2024
Statut:
aheadofprint
Résumé
Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis of SOS/VOD is associated with improved clinical outcomes. In 2023, the refined European Society for Blood and Marrow Transplantation diagnostic and severity criteria (refined EBMT criteria 2023) have been advocated. The revision has introduced new diagnostic categories, namely; probable, clinical, and proven SOS/VOD. In addition, the Sequential Organ Failure Assessment (SOFA) score has been newly incorporated into the SOS/VOD severity grading. We performed a retrospective analysis to evaluate the utility of these criteria. We analyzed 161 cases who underwent allogeneic HSCT. We identified 53 probable, 23 clinical, and 4 proven SOS/VOD cases. Probable SOS/VOD was diagnosed a median of 5.0 days earlier (interquartile range: 2-13 days, P < 0.001) than that of clinical SOS/VOD. The development of probable SOS/VOD alone was associated with a significantly inferior survival proportion compared to non-SOS/VOD (100-day survival, 86.2% vs. 94.3%, P = 0.012). The SOFA score contributed to the prediction of prognosis. Consequently, the refined EBMT criteria 2023 demonstrated the utility of SOS/VOD diagnosis and severity grading. Further investigations and improvements in these criteria are warranted.
Identifiants
pubmed: 38287083
doi: 10.1038/s41409-024-02215-4
pii: 10.1038/s41409-024-02215-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403–9. https://doi.org/10.1038/bmt.2015.283 .
doi: 10.1038/bmt.2015.283
Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl. 2011;17:1713–20. https://doi.org/10.1016/j.bbmt.2011.06.006 .
doi: 10.1016/j.bbmt.2011.06.006
Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kroger N, et al. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study. Bone Marrow Transplant. 2023. https://doi.org/10.1038/s41409-023-02077-2 .
Coutsouvelis J, Kirkpatrick CM, Dooley M, Spencer A, Kennedy G, Chau M, et al. Incidence of sinusoidal obstruction syndrome/veno-occlusive disease and treatment with defibrotide in allogeneic transplantation: a multicenter Australasian registry study. Transpl Cell Ther. 2023;29:383.e381–383.e310. https://doi.org/10.1016/j.jtct.2023.03.014 .
doi: 10.1016/j.jtct.2023.03.014
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157–68. https://doi.org/10.1016/j.bbmt.2009.08.024 .
doi: 10.1016/j.bbmt.2009.08.024
Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178:112–8. https://doi.org/10.1111/bjh.14727 .
doi: 10.1111/bjh.14727
pubmed: 28444784
pmcid: 5635854
Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018;181:816–27. https://doi.org/10.1111/bjh.15267 .
doi: 10.1111/bjh.15267
pubmed: 29767845
pmcid: 6032999
Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transpl. 2004;33:189–95. https://doi.org/10.1038/sj.bmt.1704329 .
doi: 10.1038/sj.bmt.1704329
Grupp SA, Corbacioglu S, Kang HJ, Teshima T, Khaw SL, Locatelli F, et al. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. Lancet Haematol. 2023;10:e333–45. https://doi.org/10.1016/s2352-3026(23)00011-x .
doi: 10.1016/s2352-3026(23)00011-x
pubmed: 37001534
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67. https://doi.org/10.7326/0003-4819-118-4-199302150-00003 .
doi: 10.7326/0003-4819-118-4-199302150-00003
pubmed: 8420443
Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–83. https://doi.org/10.1097/00007890-198712000-00011 .
doi: 10.1097/00007890-198712000-00011
pubmed: 3321587
Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906–12. https://doi.org/10.1038/bmt.2016.130 .
doi: 10.1038/bmt.2016.130
Cairo MS, Cooke KR, Lazarus HM, Chao N. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. Br J Haematol. 2020;190:822–36. https://doi.org/10.1111/bjh.16557 .
doi: 10.1111/bjh.16557
pubmed: 32133623
pmcid: 7483983
Ichikawa H, Yakushijin K, Miyata Y, Kanehira H, Joyce M, Hirakawa Y, et al. Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia. EJHaem. 2023;4:695–704. https://doi.org/10.1002/jha2.728 .
doi: 10.1002/jha2.728
pubmed: 37601886
pmcid: 10435725
Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2023. https://doi.org/10.1038/s41409-023-01992-8 .
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707–10. https://doi.org/10.1007/bf01709751 .
doi: 10.1007/bf01709751
pubmed: 8844239
Nishida M, Kahata K, Hayase E, Shigematsu A, Sato M, Kudo Y, et al. Novel ultrasonographic scoring system of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:1896–900. https://doi.org/10.1016/j.bbmt.2018.05.025 .
doi: 10.1016/j.bbmt.2018.05.025
Nishida M, Sugita J, Takahashi S, Iwai T, Sato M, Kudo Y, et al. Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Int J Hematol. 2021;114:94–101. https://doi.org/10.1007/s12185-021-03137-3 .
doi: 10.1007/s12185-021-03137-3
pubmed: 33763826
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367–9. https://doi.org/10.1016/j.bbmt.2008.12.497 .
doi: 10.1016/j.bbmt.2008.12.497
Yoon JH, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). Bone Marrow Transpl. 2019;54:1361–8. https://doi.org/10.1038/s41409-019-0492-6 .
doi: 10.1038/s41409-019-0492-6
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl. 2018;53:138–45. https://doi.org/10.1038/bmt.2017.161 .
doi: 10.1038/bmt.2017.161
Carreras E, How I. manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168:481–91. https://doi.org/10.1111/bjh.13215 .
doi: 10.1111/bjh.13215
pubmed: 25401997
Pai RK, van Besien K, Hart J, Artz AS, O’Donnell PH. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012;53:1552–7. https://doi.org/10.3109/10428194.2012.661052 .
doi: 10.3109/10428194.2012.661052
pubmed: 22280517
pmcid: 4482341
Corbacioglu S, Kernan NA, Pagliuca A, Ryan RJ, Tappe W, Richardson PG. Incidence of anicteric veno-occlusive disease/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients. Biol Blood Marrow Transpl. 2020;26:1342–49. https://doi.org/10.1016/j.bbmt.2020.03.011 .
doi: 10.1016/j.bbmt.2020.03.011
Mohty M, Blaise D, Peffault de Latour R, Labopin M, Bourhis JH, Bruno B, et al. Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study. Bone Marrow Transplant. 2022. https://doi.org/10.1038/s41409-022-01900-6 .
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656–65. https://doi.org/10.1182/blood-2015-10-676924 .
doi: 10.1182/blood-2015-10-676924
pubmed: 26825712
pmcid: 4817309
Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, et al. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020;4:1296–306. https://doi.org/10.1182/bloodadvances.2019000638 .
doi: 10.1182/bloodadvances.2019000638
pubmed: 32236526
pmcid: 7160275
Colecchia A, Ravaioli F, Sessa M, Alemanni VL, Dajti E, Marasco G, et al. Liver stiffness measurement allows early diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome in adult patients who undergo hematopoietic stem cell transplantation: results from a monocentric prospective study. Biol Blood Marrow Transpl. 2019;25:995–1003. https://doi.org/10.1016/j.bbmt.2019.01.019 .
doi: 10.1016/j.bbmt.2019.01.019
Debureaux PE, Bourrier P, Rautou PE, Zagdanski AM, De Boutiny M, Pagliuca S, et al. Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. Haematologica. 2021;106:2374–83. https://doi.org/10.3324/haematol.2019.245407 .
doi: 10.3324/haematol.2019.245407
pubmed: 32732366